Mercury Biopharmaceutical Corporation (6932.TWO)
TWD 13.3
(-2.56%)
TWD 13.3
(-2.56%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Operating Cash Flow | -42.14 Million | -25.84 Million | -4.78 Million | -217 Thousand | -197 Thousand |
| Net Income | -43.81 Million | -31.25 Million | -5.3 Million | -210 Thousand | -199 Thousand |
| Depreciation & Amortization | 4.07 Million | 2.74 Million | 972 Thousand | - | - |
| Deferred income taxes | - | - | - | - | - |
| Stock-based compensation | 1.82 Million | 1.12 Million | - | - | - |
| Change in working capital | -4.51 Million | 1.55 Million | -446 Thousand | -7000.00 | -4000.00 |
| Other non-cash items | -1.86 Million | 72 Thousand | 10 Thousand | - | 6000.00 |
| Investing Cash Flow | -194.43 Million | -185.39 Million | -8.02 Million | - | - |
| Investments in PPE | -13.57 Million | -68.65 Million | -7.51 Million | - | - |
| Acquisitions | - | - | - | - | - |
| Investment purchases | -554.96 Million | -108.7 Million | - | - | - |
| Sales/Maturities of investments | 378.88 Million | - | - | - | - |
| Other Investing Activities | -4.78 Million | -8.04 Million | -511 Thousand | - | - |
| Financing Cash Flow | 248.92 Million | 240.61 Million | 15.28 Million | 150 Thousand | 350 Thousand |
| Debt repayment | -1.07 Million | -41.6 Million | -394 Thousand | - | - |
| Dividends payments | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - |
| Common Stock Issuance | 250 Million | 200 Million | 15.97 Million | - | - |
| Other Financing Activities | 250 Million | 200 Million | -300 Thousand | 150 Thousand | 350 Thousand |
| Accounts receivables | - | - | - | - | - |
| Accounts payables | - | - | - | - | - |
| Inventory | - | - | - | - | - |
| Other working capital | -5.59 Million | -3.3 Million | -1.34 Million | -7000.00 | -4000.00 |
| Cash at beginning of period | 31.93 Million | 2.56 Million | 86 Thousand | 153 Thousand | - |
| Cash at end of period | 44.29 Million | 31.93 Million | 2.56 Million | 86 Thousand | 153 Thousand |
| Capital Expenditure | -13.57 Million | -68.65 Million | -7.51 Million | - | - |
| Effect of forex changes on cash | 14 Thousand | - | - | - | - |
| Net cash flow / Change in cash | 12.35 Million | 29.37 Million | 2.47 Million | -67 Thousand | 153 Thousand |
| Free Cash Flow | -55.71 Million | -94.49 Million | -12.29 Million | -217 Thousand | -197 Thousand |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -9.15 Million | -9.15 Million | -43.81 Million | -12.55 Million | -12.55 Million | -9.35 Million |
| Depreciation & Amortization | 1.61 Million | 1.61 Million | 4.07 Million | 1.18 Million | 1.18 Million | 855 Thousand |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | 311 Thousand | - | 1.82 Million | 472 Thousand | 472 Thousand | 439.5 Thousand |
| Change in working capital | 157.5 Thousand | 157.5 Thousand | -4.51 Million | -809.5 Thousand | -809.5 Thousand | -1.99 Million |
| Other non-cash items | 2.38 Million | 2.69 Million | -1.86 Million | 2.04 Million | 2.04 Million | -1.35 Million |
| Investing Cash Flow | 89.24 Million | 89.24 Million | -194.43 Million | -9.32 Million | -9.32 Million | -87.89 Million |
| Investments in PPE | -2.91 Million | -2.91 Million | -13.57 Million | -5.19 Million | -5.19 Million | -1.26 Million |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | -42.7 Million | - | -554.96 Million | - | - | - |
| Sales/Maturities of investments | 228.68 Million | - | 378.88 Million | - | - | - |
| Other Investing Activities | 92.15 Million | 92.15 Million | -4.78 Million | -4.12 Million | -4.12 Million | -86.62 Million |
| Financing Cash Flow | -23.65 Million | -23.65 Million | 248.92 Million | -271.5 Thousand | -271.5 Thousand | 124.73 Million |
| Debt repayment | - | - | -1.07 Million | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | -23.52 Million | -23.52 Million | - | - | - | - |
| Common Stock Issuance | 297 Thousand | - | 250 Million | - | - | - |
| Other Financing Activities | -134 Thousand | -134 Thousand | 250 Million | -271.5 Thousand | -271.5 Thousand | 124.73 Million |
| Accounts receivables | - | - | - | - | - | - |
| Accounts payables | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Other working capital | 157.5 Thousand | 157.5 Thousand | -5.59 Million | -809.5 Thousand | -809.5 Thousand | -1.99 Million |
| Cash at beginning of period | 44.29 Million | - | 31.93 Million | - | - | - |
| Cash at end of period | 60.89 Million | 60.89 Million | 44.29 Million | -19.26 Million | -19.26 Million | 25.44 Million |
| Capital Expenditure | -2.91 Million | -2.91 Million | -13.57 Million | -5.19 Million | -5.19 Million | -1.26 Million |
| Effect of forex changes on cash | -9500.00 | -9500.00 | 14 Thousand | 7000.00 | 7000.00 | - |
| Net cash flow / Change in cash | 16.6 Million | 60.89 Million | 12.35 Million | -19.26 Million | -19.26 Million | 25.44 Million |
| Free Cash Flow | -7.58 Million | -7.58 Million | -55.71 Million | -14.87 Million | -14.87 Million | -12.66 Million |
OPGN
603429
MICRD
8272
VIVIDM
CRAFTSMAN